Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1240 |
Name | leukemia |
Definition | A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:9145 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00620633 | Phase I | ATA520 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01396499 | Phase I | Buparlisib | Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias | Completed | USA | 0 |
NCT01703572 | Phase I | Brontictuzumab | A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | Completed | USA | 0 |
NCT01751425 | Phase II | Ruxolitinib | Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) | Terminated | USA | 0 |
NCT02028455 | Phase Ib/II | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | Active, not recruiting | USA | 0 |
NCT02091245 | Phase I | Selinexor | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Active, not recruiting | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02499861 | Phase Ib/II | Decitabine + Genistein | Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies | Completed | CAN | 0 |
NCT02512926 | Phase I | Cyclophosphamide Carfilzomib Etoposide | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | Completed | USA | CAN | 0 |
NCT02569476 | Phase I | Obinutuzumab + Zanubrutinib | BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies | Completed | USA | AUS | 1 |
NCT02786485 | Phase I | Rimiducid Rivogenlecleucel | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02932280 | Phase Ib/II | Neratinib | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | Active, not recruiting | USA | CAN | 0 |
NCT03186118 | Phase I | Autologous CD19t T-APC | Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | Active, not recruiting | USA | 0 |
NCT03229200 | FDA approved | Ibrutinib | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | Enrolling by invitation | USA | TUR | SWE | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | CAN | AUS | 4 |
NCT03884829 | Phase I | CYC140 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Terminated | USA | 0 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 0 |
NCT04526795 | Phase I | Cytarabine + Fludarabine + Pegcrisantaspase | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | Active, not recruiting | USA | 0 |
NCT04571138 | Phase Ib/II | SCRI-CAR22v2 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Recruiting | USA | 0 |
NCT04881240 | Phase I | CD19-CAR(Mem) T-cells + Cyclophosphamide + Fludarabine + Mesna | Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | Recruiting | USA | 0 |
NCT05544968 | Phase Ib/II | CD30biAb-AATC | CD30biAb-AATC for CD30+ Malignancies | Not yet recruiting | USA | 0 |